Elan Reports Second Quarter 2009 Results
Reported total revenues of $280.9m
For the three months ended 2009, Elan has reported total revenues of $280.9m, compared to $245.6m for the same period, 2008. The operating loss of the company has also decreased to $16.5m, compared to $36.0m for same period, 2008. Elan has also reported a decrease in net loss to $68.2m, compared to $71.5m for the same period, 2008.
For the six month ended period, the company has posted a revenue of $526.0m, compared to $460.3m for previous year. The operating loss for the company decreased to $71.3m, compared to $81.6m for the previous year. The net loss for the company increased to $170.8m, compared to $157.0m for the previous year.
Kelly Martin, CEO of Elan, said, During the first six months of 2009, we grew revenues, added an additional approach to Alzheimer's disease and successfully completed our strategic review with the announcement of a transformative transaction with Johnson & Johnson. Our focus will remain squarely on a disciplined and continuous investment in science and advancing our diversified clinical portfolio to patients.
Related Insight
Suppliers Directory
B&C Group - Packaging and Logistics Services
B&C Group is a Clinical Expert that provides world-class packaging and logistics services through Innovative technology and continuous improvement in Quality standards. By re-engineering logistics processes through our centres of excellence, we provide Flexible and Efficient solutions for the packaging, distribution, transport and storage or archiving of all clinical trial materials, Investigational Medicinal Products and biological specimens.
Suppliers
FANUC Robotics - Flexible Automation
FANUC Corporation is a Japanese manufacturer specialising in robotics and CNC.
Suppliers
INC Research - CRO for Drug and Device Development
INC Research is a therapeutically focused global contract research organisation (CRO) with unrivaled expertise and a reputation for conducting global clinical development programs of the highest integrity.
Suppliers
Pharmnet - Contract Research Organisation
Pharmnet is an independent CRO located in Prague, Czech Republic. Founded in 1994, it is currently a leading Czech clinical research organisation with a record of 180 Phase II-III clinical studies monitored in the Czech Republic and other CEE countries.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Pipet Controller for the Most Demanding Users
Published by VITLAB®
White Papers
Tips & Tricks - GPC/SEC: Increase Resolution and Separation Range
Published by Polymer Standards Service
White Papers
Biomarker Solutions
Published by Randox
White Papers
EZ-2: Everything a Modern Evaporator Should Be - and More
Published by Genevac
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.